These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 24263069

  • 1. Population impact of HPV vaccines: summary of early evidence.
    Hariri S, Markowitz LE, Dunne EF, Unger ER.
    J Adolesc Health; 2013 Dec; 53(6):679-82. PubMed ID: 24263069
    [Abstract] [Full Text] [Related]

  • 2. High prevalence of genital HPV infection among long-term monogamous partners of women with cervical dysplasia or genital warts-Another reason for HPV vaccination of boys.
    Rob F, Tachezy R, Pichlík T, Rob L, Kružicová Z, Hamšíková E, Šmahelová J, Hercogová J.
    Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27723194
    [Abstract] [Full Text] [Related]

  • 3. Preventing cervical cancer and genital warts - How much protection is enough for HPV vaccines?
    Stanley M.
    J Infect; 2016 Jul 05; 72 Suppl():S23-8. PubMed ID: 27211079
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Human papillomavirus vaccines and vaccine implementation.
    de Sanjosé S, Alemany L, Castellsagué X, Bosch FX.
    Womens Health (Lond); 2008 Nov 05; 4(6):595-604. PubMed ID: 19072462
    [Abstract] [Full Text] [Related]

  • 6. Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States.
    Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE.
    Vaccine; 2013 Aug 20; 31(37):3899-905. PubMed ID: 23820080
    [Abstract] [Full Text] [Related]

  • 7. [HPV vaccination with quadrivalent or nonavalent vaccine: an opportunity to eliminate genital warts as well].
    van Bergen JEAM.
    Ned Tijdschr Geneeskd; 2020 Jan 09; 164():. PubMed ID: 32073799
    [Abstract] [Full Text] [Related]

  • 8. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Drolet M, Bénard É, Pérez N, Brisson M, HPV Vaccination Impact Study Group.
    Lancet; 2019 Aug 10; 394(10197):497-509. PubMed ID: 31255301
    [Abstract] [Full Text] [Related]

  • 9. Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer.
    Chelimo C, Wouldes TA, Cameron LD, Elwood JM.
    J Infect; 2013 Mar 10; 66(3):207-17. PubMed ID: 23103285
    [Abstract] [Full Text] [Related]

  • 10. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection.
    Brisson M, Van de Velde N, De Wals P, Boily MC.
    CMAJ; 2007 Aug 28; 177(5):464-8. PubMed ID: 17709404
    [Abstract] [Full Text] [Related]

  • 11. Start early to prevent genital HPV infection-and cervical cancer.
    Heavey E.
    Nursing; 2008 May 28; 38(5):62-3. PubMed ID: 18431214
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. HPV vaccines: their pathology-based discovery, benefits, and adverse effects.
    Nicol AF, de Andrade CV, Russomano FB, Rodrigues LS, Oliveira NS, Provance DW, Nuovo GJ.
    Ann Diagn Pathol; 2015 Dec 28; 19(6):418-22. PubMed ID: 26321154
    [Abstract] [Full Text] [Related]

  • 14. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.
    Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, Donovan B, Fairley CK, Flagg EW, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV, Lemieux-Mellouki P, Markowitz L, Mboup A, Mesher D, Niccolai L, Oliphant J, Pollock KG, Soldan K, Sonnenberg P, Tabrizi SN, Tanton C, Brisson M.
    Lancet Infect Dis; 2015 May 28; 15(5):565-80. PubMed ID: 25744474
    [Abstract] [Full Text] [Related]

  • 15. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M, Lawrence D, Haig J, Anonychuk A, Demarteau N.
    BMC Public Health; 2012 Oct 13; 12():872. PubMed ID: 23061913
    [Abstract] [Full Text] [Related]

  • 16. Using the new HPV vaccines in clinical practice.
    Widdice LE, Kahn JA.
    Cleve Clin J Med; 2006 Oct 13; 73(10):929-35. PubMed ID: 17044318
    [Abstract] [Full Text] [Related]

  • 17. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.
    Petry KU, Bollaerts K, Bonanni P, Stanley M, Drury R, Joura E, Kjaer SK, Meijer CJLM, Riethmuller D, Soubeyrand B, Van Damme P, Bosch X.
    Hum Vaccin Immunother; 2018 Jul 03; 14(7):1800-1806. PubMed ID: 29553886
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of HPV immunization on the detection of cervical disease.
    Munro AJ, Cruickshank ME.
    Expert Rev Vaccines; 2014 Apr 03; 13(4):533-44. PubMed ID: 24606579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.